Editorial
A step forward in the management of a rare disease, the anaplastic lymphoma kinase-rearranged non-small cell lung cancer
Abstract
The discovery of the anaplastic lymphoma kinase (ALK) gene rearrangement as an oncogenic driver in thoracic oncology has permitted to identify a subpopulation of non-small cell lung cancer (NSCLC) that can be considered as a rare oncologic disease.
